Annals of Diagnostic Pathology
Volume 12, Issue 2 , Pages 142-145 , April 2008

Sarcomatoid carcinoma after radiation treatment of prostatic adenocarcinoma

  • Youming Huan, MD

      Affiliations

    • Department of Pathology, Mount Sinai Medical Center, New York, P.O. Box 1194, New York, NY 10029, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 212 241 5955; fax: +1 212 289 2899.
    • ,
  • Muhammad Idrees, MD

      Affiliations

    • Department of Pathology, Mount Sinai Medical Center, New York, P.O. Box 1194, New York, NY 10029, USA
    • ,
  • Michael E. Gribetz, MD

      Affiliations

    • Department of Urology, Mount Sinai Medical Center, New York, NY 10029, USA
    • ,
  • Pamela D. Unger, MD

      Affiliations

    • Department of Pathology, Mount Sinai Medical Center, New York, P.O. Box 1194, New York, NY 10029, USA

References 

  1. Lauwers GY, Schevchuk M, Armenakas N, Reuter VE. Carcinosarcoma of the prostate. Am J Surg Pathol. 1993;17(4):342–349
  2. Young RH, Srigley JR, Amin MB, Albright TM, Cubiua AL. Tumors of the prostate gland, seminal vesicles, male urethra and penis. In:  Rosai J editors. Atlas of tumor pathology, third series. Washington, DC: Armed Forces Institute of Pathology; 1998;p. 238
  3. Lopez-Beltran A, Pacelli A, Rothenberg HJ, Wollan PC, Zincke H, Blute ML. Carcinosarcoma and sarcomatoid carcinoma of the bladder: clinicopathological study of 41 cases. J Urol. 1998;159(5):1497–1503
  4. Kohn HI, Fry RJM. Radiation carcinogenesis. N Engl J Med. 1984;310:504–511
  5. Canfield SE, Gans TH, Unger P, Hall SJ. Postradiation prostatic sarcoma: de novo carcinogenesis or dedifferentiation of prostatic adenocarcinoma?. Tech Urol. 2001;7(4):294–295
  6. Neugut AI, Ahsan H, Robinson E, Ennis RD. Bladder carcinoma and other second malignancies after radiotherapy for prostate carcinoma. Cancer. 1997;79(8):1600–1604
  7. Cahan WG, Woodard HQ, Higinbotham NL, Stewart FW, Coley BL. Sarcoma arising in irradiated bone: report of 11 cases. Cancer. 1998;82(1):8–34
  8. Shannon RL, Ro JY, Grignon DJ, et al. Sarcomatoid carcinoma of the prostate. A clinicopathologic study of 12 patients. Cancer. 1992;69(11):2676–2682
  9. Dundore PA, Cheville JC, Nascimento AG, Farrow GM, Bostwick DG. Carcinosarcoma of the prostate. Report of 21 cases. Cancer. 1995;76(6):1035–1042
  10. Locke JR, Soloway MS, Evans J, Murphy WM. Osteogenic differentiation associated with x-ray therapy for adenocarcinoma of the prostatic gland. Am J Clin Pathol. 1986;85(3):375–378
  11. Delahunt B, Eble JN, Nacey JN, Grebe SK. Sarcomatoid carcinoma of the prostate: progression from adenocarcinoma is associated with p53 over-expression. Anticancer Res. 1999;19(5B):4279–4283
  12. Smith ND, Rubenstein JN, Eggener SE, Kozlowski JM. The p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder cancer. J Urol. 2003;169(4):1219–1228[review]
  13. Parsons JK, Gage WR, Nelson WG, De Marzo AM. P63 protein expression is rare in prostate adenocarcinoma: implications for cancer diagnosis and carcinogenesis. Urology. 2001;58(4):619–624
  14. Nylander K, Vojtesek B, Nenutil R, et al. Differential expression of p63 isoforms in normal tissues and neoplastic cells. J Pathol. 2002;198(4):417–427
  15. Kaufmann O, Fietze E, Mengs J, Dietel M. Value of p63 and cytokeratin 5/6 as immunohistochemical markers for the differential diagnosis of poorly differentiated and undifferentiated carcinomas. Am J Clin Pathol. 2001;116(6):823–830

PII: S1092-9134(06)00101-8

doi: 10.1016/j.anndiagpath.2006.08.008

Annals of Diagnostic Pathology
Volume 12, Issue 2 , Pages 142-145 , April 2008

Article Tools

* Image Usage & Resolution